Biogen Idec Inc (BIIB) 282.96 $BIIB
Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:20PM CDT
Infinity Pharma (INFI) reported a loss of 87 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 80 cents.
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which...
Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Thu May 08, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The webcast will be live on Wednesday, May 14, 2014 at 5:00 p.m. PT, 8:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Narrower-than-Expected Loss at AVEO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2014 loss of 5 cents per share (excluding one-time expenses).
Is Sunesis Pharmaceuticals Poised for a Breakout?
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:51AM CDT
So far this year, we've seen a handful of developmental-stage oncology companies report positive late-stage data for their therapeutic candidates, resulting in major rallies in their respective share prices. For example, Endocyte , InterMune , and...
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
AVEO Oncology Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
Perrigo Misses on Earnings and Sales, Outlook Slashed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:26PM CDT
Perrigo (PRGO) performed disappointingly in the third quarter.
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Global Hemophilia A Therapeutics Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x7lg3/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - Grifols, S.A. - BioMarin Pharmaceutical Inc. - Chugai Pharmaceutical Co., Ltd. - rEVO Biologics - Octapharma AG - Pfizer Inc. - Bayer AG - Prolor Biotech, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Green Cross Corporation - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - Inserm Transfert SA - Selecta Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - Inbiopro Solutions Pvt. Ltd. - International Biotechnology Center Generium - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/7x...mophilia_a
Fear Not, Biotech Stock 'Correction' Is Not a Bursting Bubble
at The Street - Wed May 07, 9:18AM CDT
We're not experiencing a dot-com-esque implosion in biotech stocks, no matter how loud the bears scream.
Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:00PM CDT
Perrigo (PRGO) is set to report third quarter fiscal 2014 results on May 7 before the market opens.
Sangamo BioSciences Reports First Quarter 2014 Financial Results
PR Newswire - Tue May 06, 3:02PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments.
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry
M2 - Tue May 06, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jsnl6q/global) has announced the addition of the "Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry" report to their offering. One of the main drivers in this market is the increasing number of patent expirations. A number of biopharmaceutical patents are due to expire in the near future or have already expired. This has helped propel the growth of vendors in the Global Biosimilars market. Some of the blockbuster drugs that are expected to lose patent expiry are Remicade, Humira, and Rituxan. The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. Further, the report states that one of the key challenges in the market is the risks related to drug failure. Vendors face a high level of risk due to the huge investments involved in the development stage and the possible failure of drugs when launched. Key questions answered in this report: - What will the market size be in 2016/2018 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key vendors dominating this space include: - Biocon Ltd. - Hospira Inc. - Mylan Inc. - Novartis AG - Teva Pharmaceutical Industries Ltd. - Intas Pharmaceuticals Ltd. - Dr. Reddy's Laboratories Ltd. - F. Hoffmann-La Roche Ltd. - 3SBio Inc. - Celltrion Inc. Other vendors mentioned in the report are - Actavis plc - Amgen Inc. - AstraZeneca plc - Baxter International Inc. - Biogen Idec Inc. - Bioton S.A. - Boehringer Ingelheim GmbH - Cipla Ltd. - Coherus Biosciences Inc. - Daiichi Sankyo Co. Ltd. - Emcure Pharmaceuticals Ltd. - GE Healthcare Ltd. - GeneScience Pharmaceuticals Co. Ltd. - GlaxoSmithKline plc - JCR Pharmaceuticals Co. Ltd. - iBio Inc. - LG Life Sciences Co. Ltd. - Merck & Co. Inc. - Pfizer Inc. - Ranbaxy Laboratories Ltd. - Samsung Biologics Co. Ltd. - Sanofi S.A. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/jsnl6q/global
Walgreen Hits Record Close On Sweet Easter Sales
at Investor's Business Daily - Mon May 05, 3:25PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the No. 1 U.S. drug store operator said. Shares of...
Acorda Down on Plumiaz CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 2:12PM CDT
Shares of Acorda Therapeutics, Inc. (ACOR) were down 9.8% on the news of the issuance of a Complete Response Letter (CRL) by the FDA for the New Drug Application (NDA) for Plumiaz nasal spray.
Walgreen Shares Climb Sharply in Holiday-Lifted April
at Investor's Business Daily - Mon May 05, 2:10PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the company said. Shares of Walgreen, the No. 1 U.S....
Why the Market Is Wrong About Biogen Idec Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 10:12AM CDT
Shares of Biogen Idec were initially flat when the company reported earnings last week but have seen a sell-off since then. The slump in the stock, however, was partially due to an overall downward trend in biotech at the moment, and in this...
Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:20PM CDT
Infinity Pharma (INFI) reported a loss of 87 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 80 cents.
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which...
Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Thu May 08, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The webcast will be live on Wednesday, May 14, 2014 at 5:00 p.m. PT, 8:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Narrower-than-Expected Loss at AVEO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2014 loss of 5 cents per share (excluding one-time expenses).
Is Sunesis Pharmaceuticals Poised for a Breakout?
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:51AM CDT
So far this year, we've seen a handful of developmental-stage oncology companies report positive late-stage data for their therapeutic candidates, resulting in major rallies in their respective share prices. For example, Endocyte , InterMune , and...
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
AVEO Oncology Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
Perrigo Misses on Earnings and Sales, Outlook Slashed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:26PM CDT
Perrigo (PRGO) performed disappointingly in the third quarter.
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Global Hemophilia A Therapeutics Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x7lg3/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - Grifols, S.A. - BioMarin Pharmaceutical Inc. - Chugai Pharmaceutical Co., Ltd. - rEVO Biologics - Octapharma AG - Pfizer Inc. - Bayer AG - Prolor Biotech, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Green Cross Corporation - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - Inserm Transfert SA - Selecta Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - Inbiopro Solutions Pvt. Ltd. - International Biotechnology Center Generium - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/7x...mophilia_a
Fear Not, Biotech Stock 'Correction' Is Not a Bursting Bubble
at The Street - Wed May 07, 9:18AM CDT
We're not experiencing a dot-com-esque implosion in biotech stocks, no matter how loud the bears scream.
Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:00PM CDT
Perrigo (PRGO) is set to report third quarter fiscal 2014 results on May 7 before the market opens.
Sangamo BioSciences Reports First Quarter 2014 Financial Results
PR Newswire - Tue May 06, 3:02PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments.
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry
M2 - Tue May 06, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jsnl6q/global) has announced the addition of the "Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry" report to their offering. One of the main drivers in this market is the increasing number of patent expirations. A number of biopharmaceutical patents are due to expire in the near future or have already expired. This has helped propel the growth of vendors in the Global Biosimilars market. Some of the blockbuster drugs that are expected to lose patent expiry are Remicade, Humira, and Rituxan. The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. Further, the report states that one of the key challenges in the market is the risks related to drug failure. Vendors face a high level of risk due to the huge investments involved in the development stage and the possible failure of drugs when launched. Key questions answered in this report: - What will the market size be in 2016/2018 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key vendors dominating this space include: - Biocon Ltd. - Hospira Inc. - Mylan Inc. - Novartis AG - Teva Pharmaceutical Industries Ltd. - Intas Pharmaceuticals Ltd. - Dr. Reddy's Laboratories Ltd. - F. Hoffmann-La Roche Ltd. - 3SBio Inc. - Celltrion Inc. Other vendors mentioned in the report are - Actavis plc - Amgen Inc. - AstraZeneca plc - Baxter International Inc. - Biogen Idec Inc. - Bioton S.A. - Boehringer Ingelheim GmbH - Cipla Ltd. - Coherus Biosciences Inc. - Daiichi Sankyo Co. Ltd. - Emcure Pharmaceuticals Ltd. - GE Healthcare Ltd. - GeneScience Pharmaceuticals Co. Ltd. - GlaxoSmithKline plc - JCR Pharmaceuticals Co. Ltd. - iBio Inc. - LG Life Sciences Co. Ltd. - Merck & Co. Inc. - Pfizer Inc. - Ranbaxy Laboratories Ltd. - Samsung Biologics Co. Ltd. - Sanofi S.A. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/jsnl6q/global
Walgreen Hits Record Close On Sweet Easter Sales
at Investor's Business Daily - Mon May 05, 3:25PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the No. 1 U.S. drug store operator said. Shares of...
Acorda Down on Plumiaz CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 2:12PM CDT
Shares of Acorda Therapeutics, Inc. (ACOR) were down 9.8% on the news of the issuance of a Complete Response Letter (CRL) by the FDA for the New Drug Application (NDA) for Plumiaz nasal spray.
Walgreen Shares Climb Sharply in Holiday-Lifted April
at Investor's Business Daily - Mon May 05, 2:10PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the company said. Shares of Walgreen, the No. 1 U.S....
Why the Market Is Wrong About Biogen Idec Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 10:12AM CDT
Shares of Biogen Idec were initially flat when the company reported earnings last week but have seen a sell-off since then. The slump in the stock, however, was partially due to an overall downward trend in biotech at the moment, and in this...
